Treatment of family hypercholesterolemia with PCSK9 inhibitors: an integrative review
DOI:
https://doi.org/10.33448/rsd-v10i15.23018Keywords:
Familial Hypercholesterolemia; Cardiovascular diseases; PCSK9 Inhibitors.Abstract
Familial Hypercholesterolemia is responsible for the increase in the levels of total cholesterol and LDL-cholesterol, which can cause a sharp increase in cardiovascular diseases. PCSK9 (convertase 1) is a highly expressed gene in liver, intestine and kidney. When synthesized and mutated, these small genetic variations end up helping in the regulation of LDL-Cholesterol, in addition, PCSK9 binding to LDL-Receptor can occur, thus decreasing the density of these receptors on the surface of hepatocytes. Justification: FH is considered a worldwide health problem where in Brazil we have an estimated 250,000 to 300,000 people with the disease that can lead to serious cardiovascular problems. Objective: The aim of the present work is to identify and report considerations about the latest in the treatment of familial hypercholesterolemia with PCSK9 inhibitors through an integrative literature review. Methodology: the guiding question of the research was “What can we find most current in the treatment of familial hypercholesterolemia with PCSK9 inhibitors?”, we used the following words as descriptors for the search in the PUBMED, SciELO and LILACS databases: “Hypercholesterolemia Family", "Cardiovascular Diseases" and "PCSK9 Inhibitors". In total, according to the inclusion and exclusion criteria, we obtained 8 articles for analysis.
References
Abifadel, M. et al. (2003). Mutations in PCSK9 cause autossomal dominant hypercholesterolemia. Nature Genetics. 34(2), 153-7.
Alves, A. C. S. (2014). Base genética da Hipercolesterolemia Familiar. 241f. Tese (Doutorado em Bioquímica) – Universidade de Lisboa, Lisboa
Artenstein A. W. & Opal, S. M. (2011). Proprotein convertases in health and disease. NEngl J Med. 365 (26), 2507-18.
Cesar, L. A. et al. (2014). Diretriz de Doença Coronária Estável. Arquivos Brasileiros de Cardiologia: Sociedade Brasileira de Cardiologia, 103(2), 1 – 59.
Chacra, A. P. M. & Santo, R. D. (2014). Hipercolesterolemia Famíliar: história natural. Revista da Sociedade da Cardiologia do Estado de São Paulo. 24(4), 10 – 17.
Cohen, J. et al. (2005). Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics, 37, 160-166.
Duarte, R. A. S. (2017). Hipercolesterolemia Familiar: uma nova abordagem no tratamento. 42f. Dissertação (Mestre em Medicina) - Instituto de Ciências Biomédicas Abel Salazar - Universidade do Porto.
Faludi, A. A. et al. (2017). Atualização da diretriz brasileira de dislipidemias e prevenção da aterosclerose 2017. Arquivos Brasileiros de Cardiologia: Sociedade Brasileira de Cardiologia, 109(2), .1-76.
Horton, J. D., Cohen, J. C. & Hobbs, H. H. (2009). PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 50 Suppl:S172-7
Jacik, M. Z. C. (2014). Hipercolesterolemia Familiar. 28f. Monografia (Especialização em Genética) - Universidade Federal do Paraná, Foz do Iguaçu.
Kwon, H. J., Lagage, A. T., Mcnutt, C. M., Horton, D. J. & Deisenhofer, J. (2007). Molecular basis for LDL receptor recognition by PCSK9. Proceedings of the National Academy of Sciences, 105, 1820–1825.
Lloyd, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D. & Depalma, S. M. et al. (2016). ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus. J Am Coll Cardiol. 68(1):92–125.
Pereira, C., Miname, M., Makdisse, M., Kalil Filho, R. & Santos, R. D. (2014). Associação das Doenças Arterial Periférica e Cardiovascular na Hipercolesterolemia Familiar. Arquivos brasileiros de cardiologia. 103(2), 118-123.
Sasso, M. K. D., Campos, P. S. R.C. & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto contexto – Revista de enfermagem. 17(4), 758-764.
Seidah, N. G.& Prat, A. (2012). The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery. 11, 367-383.
Silva, V. C. V. (2014). Qualidade de vida na doença arterial coronariana. 128f., Dissertação (Mestrado em Ciências da Saúde) - Universidade Federal de Pernambuco, Recife.
Souza, M. T., Silva, M. D. & Carvalho, R. (2010). Revisão integrativa: o que é e como fazer. Einstein. 8(1 Pt 1):102-6.
Ogura, M. (2017). PCSK9 inhibition in the management of familial hypercholesterolemia. Journal of cardiology vol. 71,1.
Ferrari, F. et al. (2019). PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice. Arquivos Brasileiros de Cardiologia. 112(4), 453-460.
Latimer, J., Batty, J. A., Neely, R. D. & Kunadian, V. (2016). PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis. 42(3):405-419.
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D. & Casas, J. P. (2017). PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 4.
Chapman, M. J. et al. (2015). PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Current opinion in lipidology. 26,6: 511-20.
Papademetriou, V. et al. (2018). Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia. Current pharmaceutical design. 24,31, 20: 3647-3653.
Pasta, A., Cremonini, A. L. & Pisciotta, L. et al. (2020). PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother. 21(3):353-363.
Seidah, N. G. (2017). The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Edelberto Tadeu Bernardes Júnior; Gabriel Viana Frtizen; Lucca Fantim Gomes; Thiago Tomiyoshi Moriya; Renata Calciolari Rossi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
